Serum Antireticular Cytotoxic

Antireticular Cytotoxic Serum (ACS, also known as Bogomolets serum) is a drug used in medicine to treat rheumatoid arthritis. It contains antibodies that attack the cells that cause inflammation in the joints, thereby reducing pain and swelling.

ACS was developed in the 1950s by Soviet biologist Nikolai Bogomolets and was named after him. Bogomolets used serum obtained from horses that had been vaccinated against glanders (an infectious disease) to create antibodies that attack the cells that cause rheumatoid arthritis. Later, in the 1970s, it was discovered that antibodies from Bogomolets' serum could also attack cells that cause other autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.

Today, ACS is used as an adjunct to other treatments for rheumatoid arthritis, such as immunosuppressants and biologics. It is administered intravenously or intramuscularly, usually once a week. The effects of ACS administration appear within a few weeks, and patients may notice decreased pain and improved joint function. However, like any other medicine, ACS can have side effects such as allergic reactions, infections and toxicity. Therefore, before starting treatment for ACS, you must consult your doctor and follow all his instructions.

Antireticular cytotoxic serums (ACS) are conjugated preparations consisting of agglutinating antibodies to animal red blood cells on which protozoal microorganisms (amoebas) are grown. They were first obtained by M.S. Vilensky and G.N. Mints on the adaptation of blood antigens of animals infected with amoebae